VC banks on CAR T through acoustic wave separation firm investment

By Dan Stanton contact

- Last updated on GMT

GettyImages/BackyardProduction
GettyImages/BackyardProduction

Related tags: Chemical engineering

Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.

The New Jersey-based life sciences backer has added FloDesign Sonics (FDS) to its portfolio, describing the investment as an entry into commercial CAR T and immunotherapy production advancement.

“FloDesign Sonics is fundamentally changing cell selection, handling and separation through application of gentle acoustic processing,”​ said Daniella Kranjac, co-founder and managing director of Dynamk Capital.

“We are thrilled to see the commercialisation of this technology in bioprocessing, and now FDS is set to innovate cell and gene therapy delivery, reducing cost and improving access to life-saving therapies, by enabling closed, automated, and gentle cell processing.”

Enabling the fourth pillar of modern medicine’

The firm’s acoustic wave separation (AWS) system uses a three-dimensional standing wave to trap and gather cells in the flow channel through a process called acoustophoresis. This allows particle separations that are more typically performed with porous filters or centrifuges but offers low-power, no-pressure-drop, no-clog, and no-shear, according to the company.

The platform was licensed by Pall in 2015​ as an alternative to tangential-flow filtration (TFF) and alternating tangential flow (ATF) in perfusion technologies, and more recently the firm has been pushing the tech towards cell and gene therapy applications.

Last September, FDS founder and CEO Stanley Kowalski spoke with Biopharma-Reporter on the back of a co-development deal with an undisclosed large biopharmaceutical firm to commercialise the acoustic-based unit operations in both concentration-wash and acoustic affinity cell separation (AACS) for production of a CAR T candidate.

“We believe we are really going to enable the CAR T therapies to lower the cost,”​ he told us at Biotech Week Boston. “We like to say we are enabling the fourth pillar of modern medicine.”

Related news

Show more

Related products

show more

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

CadenceILC_610x343

Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Related suppliers

Follow us

Products

View more

Webinars